Margaret E Macy
Overview
Explore the profile of Margaret E Macy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dubois S, Ogawa C, Moreno L, Mosse Y, Fischer M, Ryan A, et al.
Cancer
. 2025 Feb;
131(4):e35751.
PMID: 39932800
Background: This study evaluated the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine as monotherapy and combination therapy in children with relapsed/refractory neuroblastoma. Methods: Patients aged 2-21 years who had ...
2.
Macy M, Mody R, Reid J, Piao J, Saguilig L, Alonzo T, et al.
JCO Precis Oncol
. 2024 Sep;
8():e2400418.
PMID: 39298716
Purpose: The National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice trial assigned patients age 1-21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to...
3.
Meyers P, Federman N, Daw N, Anderson P, Davis L, Kim A, et al.
J Clin Oncol
. 2024 Jul;
42(31):3725-3734.
PMID: 38954782
Purpose: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216...
4.
Pearson A, Dubois S, Macy M, de Rojas T, Donoghue M, Weiner S, et al.
Eur J Cancer
. 2024 Jun;
207:114145.
PMID: 38936103
Phosphatidylinositol 3-kinase (PI3-K) signalling pathway is a crucial path in cancer for cell survival and thus represents an intriguing target for new paediatric anti-cancer drugs. However, the unique clinical toxicities...
5.
Slatnick L, Cost C, Garrington T, Donaldson N, Macy M
J Pediatr Hematol Oncol
. 2024 Feb;
46(2):e180-e183.
PMID: 38316140
Metastatic central nervous system (CNS) involvement is rare in pediatric primary extracranial Ewing sarcoma (ES). We describe the incidence and course of 6 patients with extracranial ES who developed metastatic...
6.
Morcos P, Schlender J, Burghaus R, Moss J, Lloyd A, Childs B, et al.
Clin Transl Sci
. 2023 Apr;
16(7):1197-1209.
PMID: 37042099
Copanlisib is an intravenously administered phosphatidylinositol 3-kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model-informed approach was undertaken to support and confirm an empirically...
7.
Goldsmith K, Park J, Kayser K, Malvar J, Chi Y, Groshen S, et al.
Nat Med
. 2023 Apr;
29(5):1092-1102.
PMID: 37012551
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children...
8.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...
9.
Lazo de la Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li Y, et al.
JCO Precis Oncol
. 2022 Nov;
6():e2200390.
PMID: 36446043
Purpose: Multiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, while very few enroll pediatric patients. We determined the types and frequency of alterations ()...
10.
Lerman B, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, et al.
J Clin Oncol
. 2022 Oct;
41(3):508-516.
PMID: 36206505
Purpose: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF)...